查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618713

多重診斷市場：按方法、應用和最終用戶分類 - 全球預測 2025-2030

Multiplexed Diagnostics Market by Method (High Density Multiplexed Assays, Low Density Multiplexed Assays, Mid-Density Multiplexed Assays), Application (Allergic Diseases, Autoimmune Diseases, Cardiology), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，多重診斷市值為149.8億美元，預計到2024年將達到173.6億美元，複合年成長率為16.62%，預計到2030年將達到439.7億美元。

多重診斷可在一次測試中同時檢測和分析多種生物標記或分析物，為提高醫療應用中的診斷準確性和效率提供了巨大潛力。對多重診斷的需求源於對全面、快速診斷解決方案日益成長的需求，這對於癌症、感染疾病和慢性病等複雜疾病的管理至關重要。這些診斷廣泛應用於實驗室、臨床環境和研究機構，涵蓋從疾病篩檢到個人化醫療的各個領域。最終用途領域主要包括醫療保健提供者、學術研究、製藥和生技公司。根據市場洞察，多重診斷市場的成長受到技術進步、慢性病盛行率上升以及對具有成本效益和高效的診斷解決方案不斷成長的需求的顯著影響。此外，基因組學和蛋白​​質組學的進步，以及人工智慧和機器學習的整合，正在提供有希望的機會。公司可以透過專注於開發易於使用的平台並結合奈米技術和生物資訊學等尖端技術來抓住這些機會。然而，高昂的初始成本、複雜的監管要求以及需要熟練人員操作先進診斷工具等挑戰正在阻礙市場成長。另一個挑戰是該領域技術變革的快速步伐，需要不斷創新和適應。創新和研究的最佳領域是開發更強大、更通用的多重平台、照護現場診斷以及在資源匱乏環境中使用的增強功能。投資於提高敏感性和特異性、同時降低成本和改善患者治療效果的研究可以推動業務成長。整體而言，市場動態的本質是動態和競爭的，凸顯了策略夥伴關係和對最尖端科技的投資對於獲得產業優勢的重要性。

主要市場統計
基準年[2023] 149.8億美元
預計年份 [2024] 173.6億美元
預測年份 [2030] 439.7億美元
複合年成長率（%） 16.62%

市場動態：快速發展的多重診斷市場的關鍵市場洞察

供給和需求的動態交互作用正在改變多重診斷市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 癌症和其他感染疾病的流行
    • 增加基因組學和個人化醫療的私人和公共資金
    • 自動化設備和分析系統的需求
  • 市場限制因素
    • 有限的多重水平和單一檢測位點之間潛在的交叉敏感性
  • 市場機會
    • 新型高階多重診斷工具簡介
    • 日益關注次世代定序解決方案的研發
  • 市場挑戰
    • 缺乏接受過處理多重診斷設備培訓的醫療保健專業人員

波特五力：駕馭多重診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解多重診斷市場的外部影響

外部宏觀環境因素在塑造多重診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解多重診斷市場的競爭狀況

對多重診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣多重診斷市場供應商績效評估

FPNV 定位矩陣是評估多重診斷市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪多重診斷市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，多重診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症和其他感染疾病的傳播
      • 增加基因組學和個人化醫療的公共和私人資金
      • 對自動化設備和分析系統的需求
    • 抑制因素
      • 多重檢測水平有限，單一檢測位點之間可能發生交叉敏感性
    • 機會
      • 介紹新型先進的多重診斷工具
      • 專注於研發活動，打造次世代定序解決方案
    • 任務
      • 缺乏接受過處理多種診斷設備訓練的醫療保健專業人員
  • 市場區隔分析
    • 方法：高密度多重檢測的使用由於其診斷準確性高而不斷增加
    • 應用：多重診斷在腫瘤疾病檢測的指數應用
    • 最終用戶：醫院需要使用多重診斷進行先進的高通量篩檢
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章多重診斷市場：依方法

  • 高密度多重偵測
  • 低密度多重偵測
  • 中密度多重檢測
  • 超高密度多重偵測

第7章多重診斷市場：按應用

  • 過敏性疾病
  • 自體免疫疾病
  • 心臟病學
  • 感染疾病
  • 腫瘤學

第 8 章 多重診斷市場：依最終使用者分類

  • 學術研究
  • 臨床調查
  • 診斷實驗室
  • 醫院
  • 製藥公司

第9章北美和南美的多重診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區多重診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲多重診斷試劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Nanopin 推出以血液為基礎的結核病檢測，為多重 HIV/TB 檢測奠定基礎
    • ChromaCode 與 Protean BioDiagnostics 建立策略夥伴關係，在美國推出基於 HDPCR 的 NSCLC 檢測
    • EDP​​ 生物技術宣布與 New Day Diagnostics 合併
    • Delta Diagnostics 在 A 輪資金籌措中籌集了 525 萬歐元（576 萬美元），以革新生物感測技術
    • ChromaCode 宣布與 MedGenome 合作，將基於 HDPCR 的診斷引入印度和中東
    • Aptitude 與 BARDA 簽署價值高達 5,400 萬美元的合作協議，開始開發用於照護現場和家庭使用的診斷技術
    • Proxim Diagnostics 宣布獲得生物梅里埃的策略投資
    • 合成生物學Start-UpsD-Nome 從 Ankur Capital、Campus Fund 籌集 150 萬美元資金
    • ALiA BioTech 的一站式診斷平台將多重檢測帶入醫學前沿
    • 安捷倫和 Akoya Biosciences 宣布合作推動生物製藥應用多重組織檢測開發
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Agilent Technologies, Inc.
  • Akoya Biosciences
  • AusDiagnostics by R-Biopharm
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardinal Health
  • Chembio
  • ChromaCode, Inc.
  • Danaher Corporation
  • Delta Diagnostics BV
  • F. Hoffmann-La Roche AG
  • Genabio Diagnostics Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Leica Biosystems
  • Medtronic PLC
  • Merck KGaA
  • NanoPin Technologies
  • Novartis AG
  • PCR Biosystems
  • QIAGEN NV
  • Quansys Biosciences Inc.
  • Seegene, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.
  • West Pharmaceutical Services
Product Code: MRR-036C5CF3A8A5

The Multiplexed Diagnostics Market was valued at USD 14.98 billion in 2023, expected to reach USD 17.36 billion in 2024, and is projected to grow at a CAGR of 16.62%, to USD 43.97 billion by 2030.

Multiplexed diagnostics involves the simultaneous detection and analysis of multiple biomarkers or analytes in a single test, offering vast potential in enhancing diagnostic accuracy and efficiency in medical applications. The necessity for multiplexed diagnostics arises from the evolving needs for comprehensive and rapid diagnostic solutions, which are essential in managing complex diseases such as cancer, infectious diseases, and chronic conditions. These diagnostics are employed extensively in laboratories, clinical settings, and research institutions for applications ranging from disease screening to personalized medicine. The end-use sectors primarily include healthcare providers, academic research, pharmaceuticals, and biotechnology firms. Market insights indicate that the growth of the multiplexed diagnostics market is significantly influenced by technological advancements, the rising prevalence of chronic diseases, and an increasing demand for cost-effective and efficient diagnostic solutions. Furthermore, advancements in genomics and proteomics, along with the integration of artificial intelligence and machine learning, present promising opportunities. Companies can seize these opportunities by focusing on developing user-friendly platforms and incorporating advanced technologies such as nanotechnology and bioinformatics. However, market growth is challenged by factors such as high initial costs, complex regulatory requirements, and the need for highly skilled personnel to operate sophisticated diagnostic tools. The fast-paced nature of technological change in the field also poses a challenge, requiring continuous innovation and adaptation. The best areas of innovation and research lie in the development of more robust and versatile multiplexing platforms, point-of-care diagnostics, and scaling up capabilities for use in low-resource settings. Investing in research that enhances sensitivity and specificity while reducing costs and improving patient outcomes can drive business growth. Overall, the nature of the multiplexed diagnostics market is dynamic and competitive, emphasizing the importance of strategic partnerships and investments in cutting-edge technologies to stay ahead in the industry.

KEY MARKET STATISTICS
Base Year [2023] USD 14.98 billion
Estimated Year [2024] USD 17.36 billion
Forecast Year [2030] USD 43.97 billion
CAGR (%) 16.62%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiplexed Diagnostics Market

The Multiplexed Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cancers and other infectious diseases
    • Rise in private-public funding for genomics & personalized medicine
    • Demand for automated equipment & analytical systems
  • Market Restraints
    • Limited multiplexing levels and possible cross-sensitivity between single detection sites
  • Market Opportunities
    • Introduction of new and advanced multiplexed diagnostic tools
    • Increasing emphasis on R&D activities to generate next-generation sequencing solutions
  • Market Challenges
    • Lack of trained healthcare professionals for handling multiplexed diagnostic equipment

Porter's Five Forces: A Strategic Tool for Navigating the Multiplexed Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiplexed Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiplexed Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiplexed Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiplexed Diagnostics Market

A detailed market share analysis in the Multiplexed Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiplexed Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiplexed Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiplexed Diagnostics Market

A strategic analysis of the Multiplexed Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiplexed Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Agilent Technologies, Inc., Akoya Biosciences, AusDiagnostics by R-Biopharm, Baxter International Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Chembio, ChromaCode, Inc., Danaher Corporation, Delta Diagnostics BV, F. Hoffmann-La Roche AG, Genabio Diagnostics Inc., Hologic, Inc., Illumina, Inc., Leica Biosystems, Medtronic PLC, Merck KGaA, NanoPin Technologies, Novartis AG, PCR Biosystems, QIAGEN N.V., Quansys Biosciences Inc., Seegene, Inc., Siemens Healthineers, Thermo Fisher Scientific, Inc., and West Pharmaceutical Services.

Market Segmentation & Coverage

This research report categorizes the Multiplexed Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Method, market is studied across High Density Multiplexed Assays, Low Density Multiplexed Assays, Mid-Density Multiplexed Assays, and Very High Density Multiplexed Assays.
  • Based on Application, market is studied across Allergic Diseases, Autoimmune Diseases, Cardiology, Infectious Diseases, and Oncology.
  • Based on End-User, market is studied across Academic Research, Clinical Research, Diagnostic Labs, Hospitals, and Pharma Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancers and other infectious diseases
      • 5.1.1.2. Rise in private-public funding for genomics & personalized medicine
      • 5.1.1.3. Demand for automated equipment & analytical systems
    • 5.1.2. Restraints
      • 5.1.2.1. Limited multiplexing levels and possible cross-sensitivity between single detection sites
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and advanced multiplexed diagnostic tools
      • 5.1.3.2. Increasing emphasis on R&D activities to generate next-generation sequencing solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of trained healthcare professionals for handling multiplexed diagnostic equipment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Method: Increased use of high-density multiplexed assays owing to their high precision in diagnostics
    • 5.2.2. Application: Exponential use of multiplexed diagnostics for oncology disease detection
    • 5.2.3. End-User: Need for advanced and high-throughput screening with multiplexed diagnostics in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multiplexed Diagnostics Market, by Method

  • 6.1. Introduction
  • 6.2. High Density Multiplexed Assays
  • 6.3. Low Density Multiplexed Assays
  • 6.4. Mid-Density Multiplexed Assays
  • 6.5. Very High Density Multiplexed Assays

7. Multiplexed Diagnostics Market, by Application

  • 7.1. Introduction
  • 7.2. Allergic Diseases
  • 7.3. Autoimmune Diseases
  • 7.4. Cardiology
  • 7.5. Infectious Diseases
  • 7.6. Oncology

8. Multiplexed Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Research
  • 8.3. Clinical Research
  • 8.4. Diagnostic Labs
  • 8.5. Hospitals
  • 8.6. Pharma Companies

9. Americas Multiplexed Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Multiplexed Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Multiplexed Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. NanoPin Launches Blood-Based TB Test, Lays Groundwork for Multiplex HIV/TB Testing
    • 12.3.2. ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the United States
    • 12.3.3. EDP Biotech Announces Merger with New Day Diagnostics
    • 12.3.4. Delta Diagnostics raises EUR 5.25 million (USD 5.76 million) in Series A Funding to Revolutionize Biosensing Technology
    • 12.3.5. ChromaCode Announces Partnership with MedGenome to Bring HDPCR-based Diagnostics to India and the Middle East
    • 12.3.6. Aptitude Receives up to USD 54 Million Partnership with BARDA to Develop Diagnostics for Point-of-Care and At-Home Use
    • 12.3.7. Proxim Diagnostics Announces Strategic Investment from bioMerieux
    • 12.3.8. Synthetic biology startup D-Nome raises USD 1.5 million in funding from Ankur Capital, Campus Fund
    • 12.3.9. ALiA BioTech's One-stop Diagnostic Platform Brings Multiplex Testing to the Medical Front Line
    • 12.3.10. Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AccuBioTech Co., Ltd.
  • 3. Agilent Technologies, Inc.
  • 4. Akoya Biosciences
  • 5. AusDiagnostics by R-Biopharm
  • 6. Baxter International Inc.
  • 7. Becton, Dickinson and Company
  • 8. Bio-Rad Laboratories, Inc.
  • 9. bioMerieux SA
  • 10. Cardinal Health
  • 11. Chembio
  • 12. ChromaCode, Inc.
  • 13. Danaher Corporation
  • 14. Delta Diagnostics BV
  • 15. F. Hoffmann-La Roche AG
  • 16. Genabio Diagnostics Inc.
  • 17. Hologic, Inc.
  • 18. Illumina, Inc.
  • 19. Leica Biosystems
  • 20. Medtronic PLC
  • 21. Merck KGaA
  • 22. NanoPin Technologies
  • 23. Novartis AG
  • 24. PCR Biosystems
  • 25. QIAGEN N.V.
  • 26. Quansys Biosciences Inc.
  • 27. Seegene, Inc.
  • 28. Siemens Healthineers
  • 29. Thermo Fisher Scientific, Inc.
  • 30. West Pharmaceutical Services

LIST OF FIGURES

  • FIGURE 1. MULTIPLEXED DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTIPLEXED DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLEXED DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY LOW DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY MID-DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY VERY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ALLERGIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023